Akamis Bio's clinical-stage NG-350A tumor gene therapy to be included as a novel combination therapeutic agent in a new cohort of the REVOLUTION platform study New cohort will assess the ability of
$30 million convertible note financing co-led by ARCH Venture Partners, Parker Institute for Cancer Immunotherapy, and Westlake Village BioPartners expands investor base to include leading US life science